A Study to Test Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Crohn's Disease
Phase 3
Withdrawn
- Conditions
- Crohn's Disease
- Interventions
- First Posted Date
- 2020-11-25
- Last Posted Date
- 2021-06-23
- Lead Sponsor
- UCB Biopharma SRL
- Registration Number
- NCT04643483
A Study to Test the Long-term Use of Oral Lacosamide in Pediatric Study Participants Who Completed NCT01964560 (EP0034) or NCT00938912 (SP848) and Received Lacosamide Treatment
- First Posted Date
- 2020-11-13
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 48
- Registration Number
- NCT04627285
- Locations
- 🇺🇦
Ep0151 606, Kiev, Ukraine
🇬🇪Ep0151 620, Tbilisi, Georgia
🇺🇦Ep0151 682, Uzhgorod, Ukraine
A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)
- First Posted Date
- 2020-10-22
- Last Posted Date
- 2024-02-05
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 43
- Registration Number
- NCT04596995
- Locations
- 🇺🇸
Tp0004 50243, Boston, Massachusetts, United States
🇨🇳Tp0004 20185, Jinan, China
🇭🇺Tp0004 40202, Győr, Hungary
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Lacosamide in Neonates With Repeated Electroencephalographic Neonatal Seizures
Phase 2
Terminated
- Conditions
- Electroencephalographic Neonatal SeizuresEpilepsy
- Interventions
- First Posted Date
- 2020-08-20
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 29
- Registration Number
- NCT04519645
- Locations
- 🇺🇸
Sp0968 118, Aurora, Colorado, United States
🇺🇸Sp0968 101, La Jolla, California, United States
🇺🇸Sp0968 108, Long Beach, California, United States
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UCB8600 in Healthy Participants, Atopic Participants, and Chronic Spontaneous Urticaria Participants
Phase 1
Terminated
- Conditions
- Healthy Study ParticipantsChronic Spontaneous Urticaria
- Interventions
- Other: Placebo
- First Posted Date
- 2020-06-23
- Last Posted Date
- 2022-07-19
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 40
- Registration Number
- NCT04444466
- Locations
- 🇧🇬
Up0086 001, Sofia, Bulgaria
A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis
Phase 3
Active, not recruiting
- Conditions
- Ankylosing SpondylitisAxial SpondyloarthritisNr-axSpar-axSpa
- Interventions
- First Posted Date
- 2020-06-18
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 508
- Registration Number
- NCT04436640
- Locations
- 🇺🇸
As0014 50056, Sarasota, Florida, United States
🇺🇸As0014 50015, Hagerstown, Maryland, United States
🇺🇸As0014 50016, Saint Louis, Missouri, United States
A Study to Assess the Safety, Pharmacokinetics and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Advanced Solid Tumors
- Interventions
- First Posted Date
- 2020-05-19
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 95
- Registration Number
- NCT04393298
- Locations
- 🇺🇸
Onc001 50414, Los Angeles, California, United States
🇬🇧Onc001 40304, Manchester, United Kingdom
🇬🇧Onc001 40305, Glasgow, United Kingdom
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Zampilimab in Adult Kidney Transplant Recipients With Chronic Allograft Injury
- First Posted Date
- 2020-04-06
- Last Posted Date
- 2022-09-21
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 3
- Registration Number
- NCT04335578
- Locations
- 🇧🇪
Cai001 101, Leuven, Belgium
🇬🇧Cai001 501, London, United Kingdom
🇪🇸Cai001 302, Hospitalet de Llobregat, Spain
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
Phase 3
Completed
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Other: PlaceboDrug: DZP
- First Posted Date
- 2020-03-04
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 321
- Registration Number
- NCT04294667
- Locations
- 🇺🇸
Sl0043 50418, Colleyville, Texas, United States
🇧🇬Sl0043 40380, Sofia, Bulgaria
🇺🇸Sl0043 50257, La Jolla, California, United States
A Study to Test the Blood Concentration of 4 Padsevonil Product Variants and the Effect of Food on Padsevonil
Phase 1
Withdrawn
- Conditions
- Healthy ParticipantsEpilepsy
- Interventions
- First Posted Date
- 2020-02-25
- Last Posted Date
- 2020-06-22
- Lead Sponsor
- UCB Biopharma SRL
- Registration Number
- NCT04283136
© Copyright 2025. All Rights Reserved by MedPath